InsiderTradr

Kimia Biosciences Limited (KIMIABL.BO)

BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic

₹30.82 (+0.00%) as of

Key statistics

Market cap
1.46B
Dividend yield
0.00%
52-week range
23.20 – 43.28
Beta
1.16
Revenue (TTM)
1.12B
Profit margin
6.41%
Volume
416.00

About Kimia Biosciences Limited

Kimia Biosciences Limited engages in the manufacturing and sale of pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) in various therapeutic categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, vitamin B1, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, anti-fungal, overactive bladder, anti-inflammatory, prokinetic agent, and hepatoprotective agent, as well as lipid lowering agent, thiamine supplement, anti-acne, NSAID, cholerectic agent, anti-bacterial, anti – ulcer/GERD, and anti-depressant. It also develops APIs for anti-psychotic, liver/metabolic disease agent, COPD/respiratory agent, COPD/respiratory agent, neuropathic pain agent, anti-migraine, and immunosuppressant. In addition, the company offers and develops KSMs, intermediates, and reagents. Further, it provides contract research and manufacturing and development services. The company also exports its products. Kimia Biosciences Limited was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019. The company was incorporated in 1993 and is based in New Delhi, India.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
New Delhi, India
Employees
205

kimiabiosciences.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks